Concord Biotech Limited (CONCORDBIO): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Concord Biotech Limited, explained in plain English.

• ▪Concord Biotech Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪CONCORDBIO closed at ₹1,268.50 on 28 October 2026.
• ▪Over the past year the shares are down 11.4%, trading between ₹987.00 and ₹1,615.00.
• ▪Reported fundamentals show a net margin of 24.84%, debt to equity of 0.12.
• ▪Our transparent MaxGrade checklist scores it B (66/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 42.25% with a maximum drawdown of -32.45% and a beta of 1.05 against NIFTY 50.

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 28 Oct 2026. Market closed.